SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Democratic gains in the midterms are driving intense debate over the market outlook, with traders concerned about possible data-center and AI regulation, tax changes, and political uncertainty. Others argue the result is already priced in and that divided government could limit policy changes, pointing to a sharp rebound in futures after the initial selloff.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Projected Democratic control of Congress is the dominant catalyst, with traders viewing the midterm losses as a major political setback for Trump and many expressing bearish sentiment on DJT amid speculation about investigations and a weakened agenda. Some argue congressional gridlock could limit policy changes, but the conversation is largely focused on the elections implications for Trump and the company.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Democratic gains in Congress are driving debate over QQQ: some traders fear tighter AI and data-center rules could weigh on the tech-heavy Nasdaq, while others see gridlock and reduced uncertainty as supportive. The community is split after a sharp selloff and rebound, with dip-buyers calling it a relief move and bears warning of further tech weakness.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Democratic election gains, including in Texas, are driving concern that SpaceX could face greater scrutiny of Musks government ties, contracts, data-center plans, and a possible Tesla merger. Traders disagree on the impact: some expect political headwinds, while others argue the projects can proceed and view the weakness as a buying opportunity.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Apples warning that memory prices are rising and expected to keep climbing has renewed bullish interest in SanDisk and other memory stocks, with traders viewing it as evidence of tight supply and pricing strength. The rebound is contested, as many remain wary of the sectors sharp recent swings and question whether AI-related demand can offset memorys cyclical risks.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros blowout quarterly results and higher full-year outlook, driven by strong AI-server demand, are the main focus. Traders are upbeat about growth and the new guidance but debate whether thin margins and lingering confidence concerns justify the muted, volatile share reaction.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention over traders reaction to perceived Democratic gains in the elections and Elon Musks political involvement. Many fear added scrutiny of Musks companies, reduced government support, and complications for a possible SpaceX merger, while some argue EV policies could benefit Tesla or view the selloff as a buying opportunity.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

A letter from 28 HOPE-3 investigators urging FDA approval of Capricors deramiocel and challenging the agencys interpretation of the trial data has renewed attention ahead of the FDA decision on the Duchenne muscular dystrophy therapy. Traders are largely optimistic that the letter strengthens the approval case, while some remain cautious about the FDAs concerns; speculation about short covering is also fueling the rally, but approval is uncertain.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL swung sharply as Democratic election gains sparked fears of tighter data-center rules and slower AI infrastructure spending, weighing on semiconductor stocks. Traders debated whether the selloff was an overreaction, while chip shares rebounded with election uncertainty easing and AMD and SMCI results supporting sentiment.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles stock-and-bond financing for its AI data-center expansion is driving debate over dilution, borrowing costs and whether future cloud revenue will generate enough cash to justify the spending. Some traders view the completed fundraising and share-price rebound as easing the overhang, while others remain concerned about debt and further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win 

LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.

Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

Why Did BCDA Stock Surge More Than 50% Today?

Equity

 BioCardia said the U.S. Food and Drug Administration confirmed that its ongoing CardiAMP Heart Failure II study could support a premarket approval application for its cell therapy.

GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain

Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.

Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.


Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

Tema ETF Trust - Tema Heart & Health ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The treatment is for patients with ischemic heart failure with reduced ejection fraction, a serious condition affecting more than one million people in the U.S.</li><li>BioCardia is preparing to submit an approval application for its cell therapy in Japan in the fourth quarter of 2026.</li><li>BCDA shares jumped past their 200-day moving average for the first time since September 2025.</li></ul>BioCardia (BCDA) surged back into investors’ radar on Friday, as a promising U.S. Food and Drug Administration indication for the company’s cell therapy to treat a type of serious heart condition boosted the stock past 50% to its highest levels in more than eight months.<a href="https://stocktwits.com/symbol/BCDA">BCDA shares</a> recorded their biggest single-day gains since August 2024 and also breached their 200-day moving average (200-DMA) for the first time since last September.<h2 class="st-heading-2">BCDA’s Heart Failure Study Could Support Premarket Application</h2>BioCardia said the FDA confirmed that its ongoing CardiAMP Heart Failure II study could support a Premarket Approval (PMA) application for the therapy. A PMA is the FDA’s review process for high-risk medical products and is required before they can be marketed in the United States.The treatment is designed for patients with ischemic heart failure with reduced ejection fraction, a serious condition that affects more than one million people in the U.S. CardiAMP uses a patient’s own bone marrow cells, which are delivered to the heart through a minimally invasive catheter procedure.The therapy has already received FDA Breakthrough Device designation. BioCardia said the FDA recognized both the unmet need for new heart failure treatments and the strength of data from its earlier CardiAMP clinical study.BioCardia is preparing to submit an approval application for its cell therapy in Japan in the fourth quarter of 2026.<h2 class="st-heading-2">What Is Retail’s Take On BCDA?</h2>Retail sentiment for BCDA on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, with ‘extremely high’ message volumes.One user said a “huge breakthrough” in heart failure treatment could be on the horizon.<stembedurl>https://stocktwits.com/GJ_Rockabilt/message/655556587</stembedurl>Another user highlighted the “huge” market potential of the therapy.<stembedurl>https://stocktwits.com/bergini/message/655546626</stembedurl>More than 109 million shares changed hands, compared to the daily average of around 371,000, according to Stocktwits data.Friday’s super-rally has driven the stock up by around 9% in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pl-stock-sinks-on-stock-offering-margin-compression/cZ0FVCWReCL">PL Stock Records Sharpest Single-Day Fall In 21 Months – Why Bullish Street Calls, Earnings Beat Failed To Turn The Tide</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

Current Price	$38.64
Prev Close	$38.77
Open	$38.74
Dividend Yield	N/A
50-Day Moving Average	$36.95
Beta	N/A
Avg. Volume	1,773.50
PE Ratio	N/A

52-Week High	$39.03
52-Week Low	$32.27
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

HRTS Fundamentals